(PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee.
Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Dr. Haag brings the number of current Supervisory Board members to seven.
“We are pleased to welcome Dr. Toralf Haag to our Supervisory Board. This appointment further deepens our expertise and experience in the Life Sciences and diagnostics,” said Lawrence Rosen, Chairman of the Supervisory Board. “This appointment of Dr. Haag is also one of the actions to come out of a review process we initiated during 2020. The Supervisory Board reaffirms its commitment to the highest level of excellence in corporate governance and working effectively with the management team to create value for QIAGEN’s stakeholders, including its shareholders.”
Dr. Haag has served since October 2018 as Chairman of the Corporate Board of Management of Voith GmbH & Co. KGaA in Germany, a global technology company with more than EUR 4 billion in annual sales and over 19,000 employees. Before joining Voith in October 2016 as Chief Financial Officer, he served for more than 11 years as CFO and Member of the Executive Committee of Lonza Group AG since August 2005. Dr. Haag began his career in 1994 as the personal assistant to the CEO of Thyssen Handelsunion AG after earning a degree in Business Administration from the University of Augsburg and a Ph.D. at the University of Kiel.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Dr. Thomas Theuringer
SENIOR DIRECTOR CORPORATE COMMUNICATIONS & HEAD OF EXTERNAL COMMUNICATIONS
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
Fax: +49 2103 29 21826
SENIOR MANAGER PUBLIC RELATIONS
Phone: +49 2103 29 11676
Fax: +49 2103 29 21676